BC Week In Review | Apr 6, 2018
Clinical News

Amyndas reports Phase I data for C3 inhibitor AMY-101

Amyndas Pharmaceuticals S.A. (Glyfada, Greece) reported data from an open-label, U.S. Phase I trial in healthy male volunteers showing that single and multiple ascending doses of subcutaneous and IV AMY-101 achieved a "very good safety...
BioCentury | Aug 11, 2017
Regulation

Foundation for inclusion

Hosting a patient-focused drug development workshop was the National Kidney Foundation Inc. ’s first step in assuming the role of facilitator to collect patient perspectives that will shape R&D for kidney disease. On Aug. 4,...
BC Extra | Aug 4, 2017
Politics & Policy

National Kidney Foundation holding patient-focused meeting with FDA

On Friday, the National Kidney Foundation (NKF) will lead a patient-focused drug development (PFDD) meeting on complement 3 glomerulopathy (C3G), a rare kidney disease, in the hopes of advancing development of innovative treatments for the...
BC Week In Review | Nov 17, 2014
Clinical News

AMY-101 regulatory update

FDA granted Orphan Drug designation to AMY-101 to treat paroxysmal nocturnal hemoglobinuria (PNH). In 2015, the company plans to start clinical testing of the complement 3 (C3) inhibitor. In August, the European Commission granted Orphan...
BC Week In Review | Sep 8, 2014
Clinical News

AMY-101 regulatory update

Amyndas said the European Commission granted Orphan Drug designation to AMY-101 to treat paroxysmal nocturnal hemoglobinuria (PNH). The company plans to start clinical testing of the complement 3 (C3) inhibitor next year. Amyndas Phamaceuticals LLC...
BioCentury | Feb 10, 2014
Emerging Company Profile

Amyndas: Complement shutdown

Transatlantic sister companies Amyndas Pharmaceuticals S.A. and Amyndas Pharmaceuticals LLC are developing therapies to treat complement-mediated disorders that could be more potent than other complement inhibitors, potentially opening up new indications. Lead candidate Amanden comes...
Items per page:
1 - 6 of 6